OR WAIT null SECS
January 28, 2022
Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.
December 01, 2021
CordenPharma will build a clinical trial development facility for manufacture of oral solid dosage drug products at its Plankstadt facility near Heidelberg, Germany.
November 16, 2021
Richard Denk, Senior Consultant Aseptic Processing and Containment, SKAN AG, discusses the evolution of aseptic processing with a particular focus on isolators.
July 16, 2021
The new lab near Continuus Pharmaceutical’s current facilities in Massachusetts will expand the company’s process development capabilities to high-potency drugs.
June 03, 2021
In addition to ADCs, other types of highly potent biologics require specialized manufacturing skills.
December 08, 2020
The company will expand its micronization abilities for highly potent drug compounds through this investment.
December 03, 2020
Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.
May 02, 2020
Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks?
March 02, 2020
Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.
October 02, 2019
Establishing OEL data and ensuring appropriate engineering controls are crucial aspects of safe handling.